Theme 3: Validate clinical effectiveness of new agents and new protocols in interventional treatment trials

Scientific Accomplishments

In preclinical triple-negative breast cancer (TNBC) models, Drs. Boerner, Polin and Heilbrun, working with Dr. LoRusso, found that poly (ADP-ribose) polymerase (PARP) inhibitors such as veliparib (ABT-888) enhanced the activity of the topoisomerase 1 inhibitor irinotecan (CPT-11). Based on these results, a Phase I clinical trial was performed to examine the tolerability of combined veliparib/ironotecan in advanced solid tumor patients. Following the dose-escalation phase, an expansion cohort was opened to perform further biomarker and genomic correlative studies in two specific TNBC populations with the combined veliparib/irinotecan.

  • Lead researchers - Drs. Boerner, Polin and Heilbrun.
  • Collaborative researcher - Dr. Li

Dr. Gadgeelwas a Principal Investigators on a phase I/II study evaluating CH5424802 (alectinib), a second generation ALK (anaplastic lymphoma kinase) inhibitor in patients with ALK positive NSCLC (non-small cell lung cancer) whose disease had progressed following treatment with the first generation ALK inhibitor crizotinib. Based on the results of the phase II trial, the drug has received ‘breakthrough designation’ by the US FDA.

  • Lead researchers - Dr. Gadgeel

The Latest From Karmanos Cancer Institute

News

Prostate Cancer Screening: Why the Conversation Matters

Among American men, prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death after lung cancer. ...

Read More

Karmanos Cancer Institute Recognizes Four Cancer Awareness Months During September

The  Barbara Ann Karmanos Cancer Institute , along with cancer centers and other organizations across the nation, recognizes and promotes awa...

Read More

IN THE NEWS: Misconceptions About Cancer Clinical Trials and How to Overcome Them

Clinical Leader Patients may not be the only ones who may be apprehensive about participating in clinical trials; some physicians may be hesitant ...

Read More
News

105.9 KISS FM | Getting a Second Opinion at Karmanos

Listen Now

WJR | Karmanos Cancer Institute Continues Its Community Education Series

Listen Now

WXYT 97.1 The Ticket | ‘Get a Mammogram’

Listen Now